2021 / 04

Next Paper
DOI: 10.24075/medet.2021.031

ORIGINAL RESEARCH

Secondary progressive multiple sclerosis in Russia: problems and needs of patients, assessment of the quality of medical care through the eyes of patients and specialists

Gayduk AYa1, Vlasov YaV2, Churakov MV3, Polyarnaya NG3, Sineok EV2
About authors

1 International Centre for Education and Research in Neuropsychiatry, Samara State Medical University, Samara, Russia

2 Samara State Medical University, Samara, Russia

3 Center of Humanitarian technologies and research «Social Dynamics», Samara, Russia

Correspondence should be addressed: Arseny Ya. Gayduk
ul. Chapayevskaya, 89, Samarskaya obl., g. Samara, 443099, Russia; a. moc.liamg@kudyag.j

About paper

Author contribution: Gayduk AI — collection, systematization and analysis of data from academic literature, text authoring, manuscript formalization; Churakov MV, Polyarnaya N. G., Sineok EV — collection, processing and analysis of socio-d emographic and clinical data; Vlasov YaV — idea, research documentation formalization and registration, manuscript editing and revision, text improvement, final approval of the manuscript for publication.

Compliance with the ethical standards: this study was approved by the Ethics Committee of the Yaroslavl State Medical University of the Ministry of Health of Russia (minutes #21 of February 8, 2018). Each participant signed and submitted the voluntary informed consent form. Adult participants filled out questionnaires voluntarily. The conducted study does not endanger the participants and complies with the biomedical ethics requirements.

Received: 2021-10-07 Accepted: 2021-11-26 Published online: 2021-12-30
|
  1. Lassmann H, Brück W, Lucchinetti CF. The immunopathology of multiple sclerosis: an overview. Brain Pathol. 2007; 17: 210–218. DOI: 10.1111/j.1750–3639.2007.00064.x. PMID: 17388952.
  2. Browne P, Chandraratna D, Angood C, Baker C, Taylor BV, Thompson AJ. Atlas of Multiple Sclerosis 2013: a growing global problem with widespread inequity. Neurology. 2014; 83(11): 1022–1024. DOI: 10.1212/ WNL.0000000000000768.
  3. Zakharova MN (ed.). Multiple sclerosis: issues of diagnosis and treatment. Moscow: Media Mente; 2018. 240 p. Available at: https://www.mmbook.ru/catalog/newrologija/ neurologyo/110022-detail. Russian.
  4. Gusev EI, Zavalishin IA, Boyko AN (eds.). Multiple sclerosis. Moscow: Real Taym; 2011. 528 p. Available at: https://www. neurology.ru/rasseyannyy- skleroz. Russian.
  5. Ponomarev VV, and Gorshova SV. “Primary progressive multiple sclerosis: delusions of neurologists and reality” Медицинские новости. 2019; 2 (293): 21–25. Russian.
  6. Evdoshenko EP, Teptsova TS, Zheleznyakova IA and others. Multiple sclerosis. Analysis of the unmet needs of the healthcare system in the Russian Federation. Ed. VV Omelyanovsky; Center for Expertise and Quality Control of Medical Care of the Ministry of Health of the Russian Federation. Moscow: [b. and.], 2020; 103 p. Russian.
  7. Thompson AJ, Baranzini SE, Geurts J, Hemmer B, Ciccarelli O. Multiple sclerosis. Lancet. 2018; 391(10130): 1622–1636.
  8. Stampanoni Bassi M, Iezzi E, Pavone L, Mandolesi G, Musella A, Gentile A, Gilio L, Centonze D, Buttari F. Modeling Resilience to Damage in Multiple Sclerosis: Plasticity Meets Connectivity. Int J Mol Sci. 2019; 21 (1): 143. DOI: 10.3390/ijms21010143.
  9. Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D. ASCEND investigators. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double- blind, placebo-c ontrolled trial with an open-label extension. Lancet Neurol. 2018; 17 (5): 405–415. DOI: 10.1016/S 1474– 4422(18)30069–3.
  10. Kappos L, Weinshenker B, Pozzilli C, Thompson AJ, Dahlke F, Beckmann K, Polman C, McFarland H. European (EU-SPMS) Interferon beta 1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board; North American (NA-SPMS) Interferon beta 1b in Secondary Progressive Multiple Sclerosis Trial Steering Committee and Independent Advisory Board.Interferon beta 1b in secondary progressive MS: a combined analysis of the two trials. Neurology. 2004; 63 (10): 1779–1787. DOI: 10.1212/01.wnl.0000145561.08973.4f.
  11. Kappos L, Bar-O r A, Cree BAC, Fox RJ, Giovannoni G, Gold R, Vermersch P, Arnold DL, Arnould S, Scherz T, Wolf C, Wallström E, Dahlke F. EXPAND Clinical Investigators. Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-b lind, randomised, phase 3 study. Lancet. 2018; 391 (10127): 1263–1273. DOI: 10.1016/S 0140–6736(18)30475–6.